Trial Profile
A Phase I Study of OTS167PO, a MELK Inhibitor, to Evaluate Safety, Tolerability and Pharmacokinetics in Patients With Advanced Breast Cancer and Dose-Expansion Study in Patients With Triple Negative Breast Cancer
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 23 Jan 2023
Price :
$35
*
At a glance
- Drugs OTS 167 (Primary)
- Indications Advanced breast cancer; Triple negative breast cancer
- Focus Adverse reactions
- Sponsors OncoTherapy Science
- 18 Jan 2023 Planned End Date changed from 1 Dec 2022 to 1 Aug 2024.
- 18 Jan 2023 Planned primary completion date changed from 1 Dec 2022 to 1 Aug 2024.
- 07 Jan 2021 Planned primary completion date changed from 1 Dec 2020 to 1 Dec 2022.